Sarepta Therapeutics, Inc. (SRPT) stock
SRPTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/3085% below fair value
$16.07+0.06 (+0.37%)
Close on Nov 13, 2026Market cap $1.70BP/E –Yield –
Sarepta Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Sarepta Therapeutics's total assets was $3.17B at Sep 30, 2026. For fiscal 2025 it was $3.35B, down 15.5% from the year before. Over ten years it grew 28.5% a year on average. The highest annual figure on record is $3.96B in fiscal 2024.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.35B | -15.5% |
| FY2024 | Dec 31, 2024 | $3.96B | +21.4% |
| FY2023 | Dec 31, 2023 | $3.26B | +4.4% |
| FY2022 | Dec 31, 2022 | $3.13B | -0.6% |
| FY2021 | Dec 31, 2021 | $3.15B | +5.5% |
| FY2020 | Dec 31, 2020 | $2.98B | +63.7% |
| FY2019 | Dec 31, 2019 | $1.82B | +11.0% |
| FY2018 | Dec 31, 2018 | $1.64B | +25.5% |
| FY2017 | Dec 31, 2017 | $1.31B | +208.4% |
| FY2016 | Dec 31, 2016 | $424.10M | +54.9% |
| FY2015 | Dec 31, 2015 | $273.78M | -7.2% |
| FY2014 | Dec 31, 2014 | $295.03M | +1.2% |
| FY2013 | Dec 31, 2013 | $291.57M | +42.2% |
| FY2012 | Dec 31, 2012 | $204.99M | +277.0% |
| FY2011 | Dec 31, 2011 | $54.37M | +18.3% |
| FY2010 | Dec 31, 2010 | $45.98M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $3.17B | -9.4% |
| Q2 FY2026 | Jun 30, 2026 | $3.19B | -13.4% |
| Q1 FY2026 | Mar 31, 2026 | $3.18B | -8.3% |
| Q4 FY2025 | Dec 31, 2025 | $3.35B | -15.5% |
| Q3 FY2025 | Sep 30, 2025 | $3.49B | -3.0% |
| Q2 FY2025 | Jun 30, 2025 | $3.68B | +7.5% |
| Q1 FY2025 | Mar 31, 2025 | $3.47B | +7.5% |
| Q4 FY2024 | Dec 31, 2024 | $3.96B | +21.4% |
| Q3 FY2024 | Sep 30, 2024 | $3.60B | +15.8% |
| Q2 FY2024 | Jun 30, 2024 | $3.42B | +9.5% |
| Q1 FY2024 | Mar 31, 2024 | $3.22B | +5.4% |
| Q4 FY2023 | Dec 31, 2023 | $3.26B | +4.4% |
| Q3 FY2023 | Sep 30, 2023 | $3.11B | -1.5% |
| Q2 FY2023 | Jun 30, 2023 | $3.13B | +4.3% |
| Q1 FY2023 | Mar 31, 2023 | $3.06B | +0.1% |
| Q4 FY2022 | Dec 31, 2022 | $3.13B | -0.6% |
| Q3 FY2022 | Sep 30, 2022 | $3.16B | +18.6% |
| Q2 FY2022 | Jun 30, 2022 | $3.00B | +8.6% |
| Q1 FY2022 | Mar 31, 2022 | $3.06B | +10.5% |
| Q4 FY2021 | Dec 31, 2021 | $3.15B | +5.5% |
| Q3 FY2021 | Sep 30, 2021 | $2.66B | -4.3% |
| Q2 FY2021 | Jun 30, 2021 | $2.76B | -4.3% |
| Q1 FY2021 | Mar 31, 2021 | $2.77B | -6.2% |
| Q4 FY2020 | Dec 31, 2020 | $2.98B | +63.7% |
| Q3 FY2020 | Sep 30, 2020 | $2.78B | +63.3% |
| Q2 FY2020 | Jun 30, 2020 | $2.88B | +65.0% |
| Q1 FY2020 | Mar 31, 2020 | $2.95B | +50.1% |
| Q4 FY2019 | Dec 31, 2019 | $1.82B | +11.0% |
| Q3 FY2019 | Sep 30, 2019 | $1.70B | +43.9% |
| Q2 FY2019 | Jun 30, 2019 | $1.75B | +40.1% |
| Q1 FY2019 | Mar 31, 2019 | $1.96B | +51.0% |
| Q4 FY2018 | Dec 31, 2018 | $1.64B | +25.5% |
| Q3 FY2018 | Sep 30, 2018 | $1.18B | +47.8% |
| Q2 FY2018 | Jun 30, 2018 | $1.25B | +177.1% |
| Q1 FY2018 | Mar 31, 2018 | $1.30B | +154.2% |
| Q4 FY2017 | Dec 31, 2017 | $1.31B | +208.4% |
| Q3 FY2017 | Sep 30, 2017 | $800.28M | – |
| Q2 FY2017 | Jun 30, 2017 | $450.14M | – |
| Q1 FY2017 | Mar 31, 2017 | $511.53M | – |
| Q4 FY2016 | Dec 31, 2016 | $424.10M | – |
See a number that looks wrong?